Literature DB >> 26130146

Clinical and cognitive implications of cerebrospinal fluid oligoclonal bands in multiple sclerosis patients.

Maria Anagnostouli1, Foteini Christidi2, Ioannis Zalonis2, Chryssoula Nikolaou3, Dimitrios Lyrakos4, Nikolaos Triantafyllou4, Ioannis Evdokimidis4, Constantinos Kilidireas4.   

Abstract

The presence of cerebrospinal fluid oligoclonal bands (CSF-OCB) in Caucasian patients with multiple sclerosis (MS) is supportive of diagnosis, though the relation with patients' clinical and specifically cognitive features has never been established or thoroughly examined. Thus, we investigated the clinical and for the first time the cognitive profile of MS patients in relation to CSF-OCB. We studied 108 patients with and without OCB and recorded demographic characteristics and detailed clinical data. A comprehensive neuropsychological battery covering different cognitive domains (attention/processing speed, memory, perception/constructions, reasoning, executive functions) was administered to MS patients and 142 demographically related healthy controls (HC). We did not find any significant differences between patients with and without OCB on demographic and clinical parameters (p > 0.05), including subtype and brain neuroimaging findings. Results revealed significantly higher cognitive scores in HC compared to both OCB subgroups, with more widespread cognitive changes in patients with OCB. Analysis between OCB subgroups showed significantly worse performance in patients with OCB on visual memory (Rey's complex figure test-recall; p = 0.006). Concluding, the presence of CSF-OCB in our MS patients tends to be related to more widespread cognitive changes, specifically worse visual memory. Future longitudinal studies in different populations are warranted to better clarify the clinical and cognitive characteristics related to CSF-OCB which could serve as early biomarker in disease monitoring.

Entities:  

Keywords:  Brain MRI; Cognitive function; Corpus callosum; Multiple sclerosis; Neuropsychological assessment; Oligoclonal bands

Mesh:

Substances:

Year:  2015        PMID: 26130146     DOI: 10.1007/s10072-015-2303-1

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  41 in total

1.  Association of HLA-DRB1*15 allele and CSF oligoclonal bands in a Spanish multiple sclerosis cohort.

Authors:  L Romero-Pinel; S Martínez-Yélamos; L Bau; E Matas; L Gubieras; J María Pujal; F Morandeira; J Bas; T Arbizu
Journal:  Eur J Neurol       Date:  2011-03-21       Impact factor: 6.089

2.  Prevalence of cerebrospinal fluid oligoclonal IgG bands in Greek patients with clinically isolated syndrome and multiple sclerosis.

Authors:  E Andreadou; S Chatzipanagiotou; V C Constantinides; A Rombos; E Stamboulis; C Nicolaou
Journal:  Clin Neurol Neurosurg       Date:  2013-08-13       Impact factor: 1.876

3.  Cognition in the early stage of multiple sclerosis.

Authors:  Doreen Schulz; Bruno Kopp; Annett Kunkel; Jürgen H Faiss
Journal:  J Neurol       Date:  2006-04-11       Impact factor: 4.849

4.  CSF oligoclonal bands, MRI, and the diagnosis of multiple sclerosis.

Authors:  T Pirttilä; T Nurmikko
Journal:  Acta Neurol Scand       Date:  1995-12       Impact factor: 3.209

5.  Cognitive impairment in different MS subtypes and clinically isolated syndromes.

Authors:  Constantin Potagas; Erasmia Giogkaraki; Georgios Koutsis; Dimitrios Mandellos; Erifylli Tsirempolou; Constantin Sfagos; Demetris Vassilopoulos
Journal:  J Neurol Sci       Date:  2007-11-13       Impact factor: 3.181

6.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

Review 7.  Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report.

Authors:  M Andersson; J Alvarez-Cermeño; G Bernardi; I Cogato; P Fredman; J Frederiksen; S Fredrikson; P Gallo; L M Grimaldi; M Grønning
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-08       Impact factor: 10.154

8.  Clinical and MRI characterization of MS patients with a pure and severe cognitive onset.

Authors:  Rana Assouad; Celine Louapre; Ayman Tourbah; Caroline Papeix; Damien Galanaud; Catherine Lubetzki; Bruno Stankoff
Journal:  Clin Neurol Neurosurg       Date:  2014-08-20       Impact factor: 1.876

9.  'Subclinical MS': follow-up of four cases.

Authors:  B Hakiki; B Goretti; E Portaccio; V Zipoli; M P Amato
Journal:  Eur J Neurol       Date:  2008-08       Impact factor: 6.089

10.  MRI criteria in MS patients with negative and positive oligoclonal bands: equal fulfillment of Barkhof's criteria but different lesion patterns.

Authors:  Hagen B Huttner; Peter D Schellinger; Tobias Struffert; Gregor Richter; Tobias Engelhorn; Teresa Bassemir; Mathias Mäurer; Meritxell Garcia; Stefan Schwab; Martin Köhrmann; Arnd Doerfler
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

View more
  7 in total

Review 1.  The role of melatonin in Multiple Sclerosis.

Authors:  Charalampos Skarlis; Maria Anagnostouli
Journal:  Neurol Sci       Date:  2019-12-16       Impact factor: 3.307

Review 2.  Therapeutic potential of curcumin for multiple sclerosis.

Authors:  Munibah Qureshi; Ebtesam A Al-Suhaimi; Fazli Wahid; Omer Shehzad; Adeeb Shehzad
Journal:  Neurol Sci       Date:  2017-10-27       Impact factor: 3.307

3.  Extreme Diversity of IgGs Against Histones, DNA, and Myelin Basic Protein in the Cerebrospinal Fluid and Blood of Patients with Multiple Sclerosis.

Authors:  Irina A Kostrikina; Valentina N Buneva; Enrico Granieri; Georgy A Nevinsky
Journal:  Biomolecules       Date:  2020-04-18

4.  Assessing the presence of oligoclonal IgM bands as a prognostic biomarker of cognitive decline in the early stages of multiple sclerosis.

Authors:  Clàudia Coll-Martinez; Ester Quintana; Judit Salavedra-Pont; Maria Buxó; Marina González-Del-Rio; Immaculada Gómez; María Muñoz-San Martín; Luisa María Villar; Gary Álvarez-Bravo; René Robles-Cedeño; Lluís Ramió-Torrentà; Jordi Gich
Journal:  Brain Behav       Date:  2021-11-18       Impact factor: 2.708

5.  Advanced MRI features in relapsing multiple sclerosis patients with and without CSF oligoclonal IgG bands.

Authors:  Lin Zhao; Jill Abrigo; Qianyun Chen; Cheryl Au; Angel Ng; Ping Fan; Vincent Mok; Wei Qiu; Allan G Kermode; Alexander Y Lau
Journal:  Sci Rep       Date:  2020-08-13       Impact factor: 4.379

6.  Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers.

Authors:  Lorenzo Gaetani; Nicola Salvadori; Elena Chipi; Lucia Gentili; Angela Borrelli; Lucilla Parnetti; Massimiliano Di Filippo
Journal:  Neural Regen Res       Date:  2021-01       Impact factor: 5.135

7.  Cognitive Decline in Multiple Sclerosis Is Related to the Progression of Retinal Atrophy and Presence of Oligoclonal Bands: A 5-Year Follow-Up Study.

Authors:  Natasa Giedraitiene; Egle Drukteiniene; Rasa Kizlaitiene; Andrius Cimbalas; Rimvydas Asoklis; Gintaras Kaubrys
Journal:  Front Neurol       Date:  2021-07-13       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.